SuperworthRhythm Pharmaceuticals RYTM
- Market cap
- $6.1B
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 25.6×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $239.9M
- +54% on a year ago
- Net margin
- −85.6%
- Free cash flow yield
- n/m
- not a meaningful number
Rhythm Pharmaceuticals trades at 25.6× sales. Its trailing earnings are negative, so it has no PE. Revenue was $239.9M over the last twelve months, up 54% on a year earlier with a −86% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $22.5M+425% | $24.2M+176% | $26M+126% | $29.1M+51% | $33.3M+48% | $41.8M+73% | $32.7M+26% | $48.5M+67% | $51.3M+54% | $57.3M+37% | $60.1M+84% | $71.3M+47% | |
| Cost of revenue | $2.4M+385% | $3.2M+215% | $2.8M+98% | $2.9M+32% | $3.8M+59% | $3.8M+17% | $3.6M+30% | $5.5M+88% | $5.5M+44% | $4.8M+27% | $7.2M+96% | $8.9M+61% |
| Gross profit | $20.1M+431% | $21M+171% | $23.2M+131% | $26.1M+54% | $29.4M+46% | $38M+81% | $29.1M+26% | $43M+64% | $45.8M+56% | $52.5M+38% | $53M+82% | $62.3M+45% |
| R&D | $33.6M+59% | $29.9M+27% | $128.7M+239% | $30.2M−10% | $37.9M+13% | $41.2M+38% | $37M−71% | $42.3M+40% | $46M+21% | $42M+2% | $41.7M+13% | $43.4M+3% |
| SG&A | $30.5M+39% | $32.4M+23% | $34.4M+40% | $36.4M+21% | $35.4M+16% | $38.1M+18% | $39.1M+14% | $45.9M+26% | $52.4M+48% | $57.5M+51% | $63.6M+63% | $67.4M+47% |
| −$44M+12% | −$41.3M−2% | −$139.9M+166% | −$40.5M−13% | −$43.9M−0% | −$41.3M+0% | −$47M−66% | −$45.3M+12% | −$52.7M+20% | −$47.1M+14% | −$52.4M+11% | −$48.6M+7% | |
| Interest expense | $3.1M+47% | $4.5M+51% | $4.8M+55% | $4.6M+39% | $5.2M+67% | $5.4M+20% | $5.4M+14% | $5.8M+26% | $4.7M−10% | $4.6M−15% | $4.6M−15% | $4.5M−22% |
| Pre-tax income | −$43.8M+7% | −$41.4M−3% | −$141.1M+170% | −$31.8M−32% | −$44M+0% | −$43.4M+5% | −$49.4M−65% | −$46.3M+46% | −$52.8M+20% | −$47.5M+10% | −$55.1M+12% | −$48.9M+6% |
| $368K | $196K | $300K | $479K | −$344K | −$90K | $80K−73% | $337K−30% | $111K | −$31K−66% | $545K+581% | $444K+32% | |
| Net income | −$44.2M+8% | −$41.6M−2% | −$141.4M+171% | −$32.3M−31% | −$43.6M−1% | −$43.3M+4% | −$49.5M−65% | −$46.6M+45% | −$52.9M+21% | −$47.5M+10% | −$55.6M+12% | −$49.3M+6% |
| −$0.76−4% | −$0.70−7% | −$2.35+155% | −$0.55−33% | −$0.73−4% | −$0.72+3% | −$0.81−66% | −$0.75+36% | −$0.82+12% | −$0.73+1% | −$0.83+3% | −$0.73−3% | |
| 57.9M+13% | 59.2M+5% | 60.1M+6% | 61M+7% | 61.2M+6% | 61.6M+4% | 63.1M+5% | 63.7M+4% | 66.3M+8% | 66.9M+9% | 68M+8% | 68.6M+8% |
Gross profit: 22 periods, Q1 FY21 to Q2 FY26: not printed by the filing, worked out from its own lines.
Net income: Q4 FY20: not printed by the filing, worked out from its own lines.
EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 10 periods, Q4 FY16 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Rhythm Pharmaceuticals' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| RYTMRhythm Pharmaceuticals | $6.1B | n/m | n/a | 25.6× | +54% | −85.6% | |
| LGNDLigand Pharmaceuticals | $6.1B | 32.3× | 37.7× | 20.8× | +55% | 67.9% | |
| KNSAKiniksa Pharmaceuticals International | $6B | 79.1× | 85.3× | 7.1× | +59% | 9.6% | |
| AMRXAmneal Pharmaceuticals | $6.5B | 41.6× | 51.5× | 2.1× | +9% | 5.0% | |
| ALKSAlkermes plc. | $7.3B | 115× | 16.0× | 4.4× | +11% | 4.0% | |
| TGTXTG Therapeutics | $8.3B | 19.8× | 19.4× | 10.4× | +76% | 55.2% | |
| PTGXProtagonist Therapeutics | $9B | 134× | 58.3× | 31.8× | +35% | 29.4% | |
| CORTCorcept Therapeutics | $9.3B | 204× | 28.3× | 11.2× | +16% | 6.6% | |
| INDVIndivior Pharmaceuticals | $4.1B | 12.4× | 20.1× | 3.1× | +13% | 26.7% | |
| ARQTArcutis Biotherapeutics | $3.9B | 142× | 115× | 8.5× | +76% | 6.1% | |
| LQDALiquidia | $3.8B | 30.7× | 53.6× | 8.5× | n/m | 30.7% | |
| Peer median | $6.3B | 60.3× | 44.6× | 8.5× | +35% | 18.1% |
Investors who own it
Investors we follow who held Rhythm Pharmaceuticals at the end of Jun 30, 2026, from their 13F filings.
- Stanley DruckenmillerDuquesne Family Office0.5% of portfolionew
More on Rhythm Pharmaceuticals
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .